MSH6 and colorectal cancer: Our analysis revealed a correlation between MSH6 gene status and both progression‐free survival (PFS) and objective response rate (ORR) in patients with MSI‐H colorectal cancer who underwent immune therapy, suggesting that MSI‐H colorectal cancer patients with MSH6 mutations exhibited better response to immune therapy.